Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Rohan Dharmakumar
Summary
The objective of this randomized, controlled pilot study is to determine the efficacy of Deferiprone to reduce the amount of free iron inside the hemorrhagic zone of myocardial infarction among hemorrhagic myocardial infarction patients.
Eligibility
- Age range
- 18–79 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria 1. Age 18-79 years 2. Index Anterior wall STEMI 3. Emergency coronary angiogram with primary PCI Exclusion Criteria 1. Prior history of MI / PCI / coronary artery bypass graft (CABG) within previous 1 year 2. Patients with previous history of left ventricular ejection fraction (LVEF) \< 40% 3. Use of investigational drugs or devices 30 days prior to randomization 4. Known allergy or contra-indication to gadolinium/contrast agents 5. eGFR \< 30 ml/kg/min 6. Any contraindication against cardiac MRI (such as metal implants) 7. Women who are pregnant or breastfeeding. Women o…
Interventions
- DrugDeferiprone Tablets
Deferiprone tablets are the active medication for the active arm of the study groups. Randomization will be done by investigational drug services pharmacist and intervention will be double-blinded to investigators and patients.
- DrugPlacebo
Deferiprone placebo is the non-medicated formulation for a control arm of the study groups.
Location
- IU Methodist Hospital (IUHealth)Indianapolis, Indiana